↑ 疾患リストへ ← 戻る

 279. 巨大静脈奇形(頚部口腔咽頭びまん性病変) [臨床試験数:7,薬物数:16(DrugBank:6),標的遺伝子数:1,標的パスウェイ数:43] 

Searched query = "Huge venous malformation with cervical, oral and pharyngeal diffuse lesion", "Huge venous malformation", "Venous malformation"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"    Synonyms (DrugBank) were also searched for.
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03767660July 31, 201818 December 2018Efficacy of Rapamycin (Sirolimus) in the Treatment of BRBNS, Hereditary or Sporadic Venous MalformationEfficacy of Rapamycin (Sirolimus) in the Treatment of Blue Rubber Bleb Nevus Syndrome, Hereditary or Sporadic Venous MalformationBlue Rubber Bleb Nevus Syndrome;Venous MalformationDrug: RapamycinPeking Union Medical College HospitalAir Force General Hospital of the PLA;Chinese Academy of Medical SciencesRecruitingN/AN/AAll20Phase 4China
2ChiCTR-OIB-150074552015-03-1818 April 2017Effect of sclerotherapy on venous malformation associated with localized intravascular coagulopathy: A prospective, before-after controlled studyEffect of sclerotherapy on venous malformation associated with localized intravascular coagulopathy: A prospective, before-after controlled studyvenous malformation1:sclerotherapy with ethanol;Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of MedicineRecruitingBoth1:40;Phase 1 studyChina
3NCT01347294August 201116 December 2017Compare Two Different Sclerosing Agents in the Treatment of Venous MalformationsCompare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous MalformationsVenous MalformationDrug: Bleomycin;Drug: Fibrovein;Drug: Bleomycin + FibroveinOslo University HospitalRecruiting12 Years80 YearsAll126Phase 4Norway
4JPRN-jRCTs07118006723/10/200910 September 2019Clinical research of intralesional sclerotherapy in the oral and maxillofacial regionClinical research for safty and efficacy in intralesional sclerotherapy with ethanolamine oleate for subcutaneous venous malformation in the oral and maxillofacial region - EOST-OMSVenous malformation in the oral and maxillofacial region
Sclerotherapy, Venous malformation, ethanolamine oleate;angioma, venous
Single arm study, open (masking not used), no assignment
All procedures will be done with oral surgeon and radiologist in angiography room. (For superficial lesion, procedures will be done with intermittent simple X-ray for reduction of exposure, despite using angiography to confirm drainage veins in oral and maxillofacial outpatient clinic.)
1. Local anesthesia into the lesion.
2. Puncture with 22-24G needle and confirm the backflow of blood.
3. Stabilize the needle and check the distribution and blood flow of the lesion by angiography and computed tomography (CT) with contrast medium. If there is any risk that sclerosing agent will escape whole body, we must decide the cancellation of the trial. If we can block the drainage vein over 5 minutes, we decide that the trial can continue. (For superficial lesions, we inject contrast medium in oral and maxillofacial outpatient clinic and confirm retention of contrast medium using intermittent simple X-ray.)
4. Treat with injection 5% ethanolamine oleate(EO) (diluted by Iopamiron 300) . Volume of the 5%EO will be decided by situation, but the maximum volume is 20ml (5% EO) by one treatment. After 5 minites, the 5%EO collect as possible.
5. Check the hemostasis of the injection point(s).
Atsushi DanjoRecruitingNot applicableNot applicableBoth25Phase 2none
5NCT00975819October 200919 February 2015Safety and Efficacy Study of Sirolimus in Complicated Vascular AnomaliesA Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular AnomaliesKaposiform Hemangioendotheliomas;Tufted Angioma;Capillary Venous Lymphatic Malformation;Venous Lymphatic Malformation;Microcystic Lymphatic Malformation;Mucocutaneous Lymphangiomatosis and Thrombocytopenia;Capillary Lymphatic Arterial Venous Malformations;PTEN Overgrowth Syndrome With Vascular Anomaly;Lymphangiectasia SyndromesDrug: sirolimusChildren's Hospital Medical Center, CincinnatiNot recruitingN/A31 YearsBoth60Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2009-011276-29-FR21/08/200919 March 2012Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study.Systemic and local diffusion of ethanol after administration of ethanol 96% formulated in a gel (L0122 Gel) and ethanol 98% solution (absolute ethanol) by the percutaneous route, in patients with congenital venous malformations (CVM): pharmacokinetic, pharmacodynamic and clinical study.patients with congenital venous malformations (CVM)Product Name: Ethanol gel
Product Code: L0122
Pharmaceutical Form: Gel for injection
CAS Number: 64-17-5
Other descriptive name: ETHANOL (96 PER CENT)
Concentration unit: % (W/W) percent weight/weight
Concentration type: equal
Concentration number: 94.12-
Trade Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection
Product Name: Dehydrated Alcohol (Absolute Alcohol) BP for Injection
Pharmaceutical Form: Solution for injection
CAS Number: 64-17-5
Other descriptive name: ETHANOL BP
Concentration unit: % (V/V) percent volume/volume
Concentration type: equal
Concentration number: 100-
ORFAGENAuthorisedFemale: yes
Male: yes
24France
7NCT00462462May 200719 October 2017Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.Systemic and Local Diffusion of Ethanol After Administration of Ethanol 96% Formulated in a Gel and Ethanol 98% Solution by the Percutaneous Route, in Patients With Congenital Venous Malformations:Pharmacokinetic, Pharmacodynamic and Clinical Study.Congenital Venous MalformationDrug: Ethanol 96% Gel;Drug: Ethanol 98% SolutionOrfagenFDA Office of Orphan Products DevelopmentNot recruiting12 YearsN/AAll32Phase 2United States;France

先頭へ